Evidence map›Paper›PMID 29232838›Full record

ArticleMolecules (Basel, Switzerland)2017

Design and Synthesis of New Benzothiazole Compounds as Selective hMAO-B Inhibitors.

Sinem Ilgın, Derya Osmaniye, Serkan Levent, Begüm Nurpelin Sağlık, Ulviye Acar Çevik, Betül Kaya Çavuşoğlu, Yusuf Özkay, Zafer Asım Kaplancıklı

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Design, Synthesis,ACS omega · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Synthesis,Journal of enzyme inhibition and medicinal chemistry · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sinem IlgınDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. silgin@anadolu.edu.tr.
Derya OsmaniyeDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. dosmaniye@anadolu.edu.tr.
Serkan LeventDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. serkanlevent@anadolu.edu.tr.
Begüm Nurpelin SağlıkDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. bnsaglik@anadolu.edu.tr.
Ulviye Acar ÇevikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. uacar@anadolu.edu.tr.
Betül Kaya ÇavuşoğluDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. betulkaya@anadolu.edu.tr.
Yusuf ÖzkayDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. yozkay@anadolu.edu.tr.
Zafer Asım KaplancıklıDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu Universty, 26470, Eskişehir, Turkey. zakaplan@anadolu.edu.tr.ORCID 0000-0003-2252-0923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current work a new class of novel benzothiazole-hydrazone derivatives was designed and synthesized as

Indexed as

AnimalsBenzothiazolesDrug DesignHumansMiceMolecular Docking SimulationMolecular StructureMonoamine OxidaseMonoamine Oxidase InhibitorsNIH 3T3 CellsStructure-Activity RelationshipBenzothiazolesMonoamine Oxidasemonoamine oxidase A, humanMonoamine Oxidase Inhibitorsbenzothiazolecytotoxicitydocking studyhydrazoneMAO enzyme inhibition

Identifiers

PMID29232838
PMCPMC6149824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.